Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Expert Review of Neurotherapeutics|April 28, 2005
Pharmacological treatment strategies for schizophreniaJ P Lindenmayer, Anzalee Khan
Schizophrenia Research|September 21, 2010
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophreniaJean-Pierre Lindenmayer, Anzalee Khan
BMC Psychiatry|November 18, 2011
Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS)Anzalee Khan, Charles Lewis, Jean-Pierre Lindenmayer
AMIA ... Annual Symposium Proceedings. AMIA Symposium|November 13, 2008
Interface for electronic data capture systems for clinical trials by optimal utilization of available hospital resourcesSashank Kaushik, Anzalee Khan, Saurabh Kaushik, et al.
Innovations in Clinical Neuroscience|February 8, 2018
Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional ExperiencePhilip D Harvey, Anzalee Khan, Richard S E Keefe
Psychiatry Research|January 26, 2019
Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomesPhilip D Harvey, Anzalee Khan, Alexandra Atkins, et al.
The Psychiatric Clinics of North America|August 28, 2007
Schizophrenia: measurements of psychopathologyJ P Lindenmayer, Philip D Harvey, Anzalee Khan, et al.
Journal of Clinical Psychopharmacology|February 25, 2011
A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorderJean-Pierre Lindenmayer, Leslie Citrome, Anzalee Khan, et al.
The Journal of Clinical Psychiatry|March 29, 2007
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophreniaJean-Pierre Lindenmayer, Anzalee Khan, Adel Iskander, et al.
Schizophrenia Research|October 19, 2020
The psychometric properties of the Self-Evaluation of Negative Symptoms Scale (SNS) in treatment-resistant schizophrenia (TRS)Abraham Goldring, Sophia Borne, Amanda Hefner, et al.
Pageof 5